AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

Michael Faerm is appointed Chief Financial Officer of AtaiBeckley, effective March 9, 2026, with responsibility for the company’s financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who served as Chief Financial Officer since 2024, transitions to Chief Accounting Officer on the effective date, with a mandate to continue leading accounting and financial operations alongside Faerm. The release frames the leadership change in the context of AtaiBeckley’s late-stage and clinical pipeline, including BPL-003 planning for Phase 3 and ongoing development of VLS-01 (DMT buccal film) and EMP-01 ((R)-MDMA HCl) for mental health indications.